Literature DB >> 15004527

Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells.

John G Shelton1, William L Blalock, Edmond R White, Linda S Steelman, James A McCubrey.   

Abstract

Multiple signal transduction pathways, including the Raf/MEK/ERK and PI3K/Akt kinase cascades, play critical roles in transducing growth signals from activated cell surface receptors. Using conditionally and constitutively-active forms of MEK1 and either PI3K or Akt, we demonstrate synergy between these kinases in relieving cytokine-dependence of the FDC-P1 hematopoietic cell line. Cytokine-independent cells were obtained from DeltaMEK1:ER-infected cells at a frequency of 5 x 10(-5) indicating that low frequency of cells expressing beta-estradiol-regulated DeltaMEK1:ER became factor-independent, while activated PI3K or Akt by themselves did not relieve cytokine-dependence. In contrast, cytokine-independent cells were recovered approximately 25 to 250-fold more frequently from DeltaMEK1:ER infected cells also infected with either activated PI3K or Akt. MEK/PI3K and MEK/Akt-responsive cells could be maintained long-term as long as either beta-estradiol or the estrogen receptor antagonist 4-hydroxy-tamoxifen (4HT) were provided. The MEK/PI3K/Akt responsive cells were sensitive to both MEK and PI3K/Akt/p70S6K inhibitors. Synergy was observed when inhibitors which targeted both pathways were added together. These results indicate that there is synergy between the Raf/MEK/ERK and PI3K/Akt pathways in terms of abrogation of cytokine-dependence of hematopoietic cells. Likewise, suppression of multiple signal transduction pathways is a more effective means to inhibit cell cycle progression and induce apoptosis in leukemic cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004527

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

1.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

2.  The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.

Authors:  Juraj Bodo; Xiaoxian Zhao; Arishya Sharma; Brian T Hill; Craig A Portell; Brian J Lannutti; Alexandru Almasan; Eric D Hsi
Journal:  Br J Haematol       Date:  2013-07-25       Impact factor: 6.998

3.  Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.

Authors:  M S I Abaza; A M Bahman; R J Al-Attiyah; A M Kollamparambil
Journal:  Tumour Biol       Date:  2012-07-19

4.  Gene transcripts associated with BMI in the motor cortex and caudate nucleus of calorie restricted rhesus monkeys.

Authors:  Amanda C Mitchell; Rehana K Leak; Michael J Zigmond; Judy L Cameron; Károly Mirnics
Journal:  Genomics       Date:  2011-12-29       Impact factor: 5.736

5.  Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia.

Authors:  Federica Falà; William L Blalock; Pier Luigi Tazzari; Alessandra Cappellini; Francesca Chiarini; Giovanni Martinelli; Agostino Tafuri; James A McCubrey; Lucio Cocco; Alberto M Martelli
Journal:  Mol Pharmacol       Date:  2008-06-24       Impact factor: 4.436

6.  The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt.

Authors:  P R Somanath; J Vijai; J V Kichina; T Byzova; E S Kandel
Journal:  Oncogene       Date:  2009-05-04       Impact factor: 9.867

Review 7.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

Review 8.  The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.

Authors:  Jessica Lawrence; Richard Nho
Journal:  Int J Mol Sci       Date:  2018-03-08       Impact factor: 5.923

9.  Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.

Authors:  Esther P Jane; Daniel R Premkumar; Steven O Addo-Yobo; Ian F Pollack
Journal:  J Pharmacol Exp Ther       Date:  2009-07-21       Impact factor: 4.030

10.  Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.

Authors:  Ting Li; Qunling Zhang; Jian Zhang; Gong Yang; Zhimin Shao; Jianmin Luo; Minhao Fan; Chen Ni; Zhenhua Wu; Xichun Hu
Journal:  BMC Cancer       Date:  2014-02-16       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.